PharmExec Direct:
Having trouble viewing this e-mail? Click here.
You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile
PharmExec Direct | From the editors of Pharmaceutical Executive Visit the PharmExec website
Send Us Some Feedback
 
December 2, 2010 | ISSUE NUMBER 177 VOL 8

Regulatory
A Fine Line Between Evolution and Regulation
The strict regulatory divide between market authorization and price reimbursement is crumbling in the US. Ansis Helmanis asks, Is industry prepared to adapt or challenge?

Legal
Law On Commercial Use of Physician Information Overturned
US Court of Appeals ruling is likely to force state legislatures considering such bans to fine tune their approach.

Europe
Ireland’s Economic Rescue Package to Sting Pharma
Ireland’s favorable level of corporation tax remains untouched by the country’s bailout package, but drugmakers will still feel the pinch of the healthcare cuts.

Pharma Advertising
What Was Your Favorite Pharma Ad of 2010?
Pharm Exec has begun its search for the Ad Stars, our annual feature honoring the best in Rx advertising—and we want your input.

// PharmaNet Development Group (Princeton, N.J.) appointed Dr. Chris Beaver as Director, Immunochemistry Services.// Professor Victor S. Dorodny was appointed Chief Medical Officer and Global Practice Leader for US Tele-Medicine (Beverly Hills, Calif.). // Lupin Ltd. appointed Paul McGarty as President of its US subsidiary, Lupin Pharmaceuticals (Baltimore). //

Dec 5–7: Mayo Clincil 2010 Symposium: Achieving the Vision — Advancing High-Value Health Care
Bethesda, MD


Dec 8–9: CMAC 2010 – Commercialization and Market Access Congress Orlando, FL


Jan 11–12: The State of Clinical Development Costs
Philadelphia, PA

 
CBI’s 8th Pharmaceutical Compliance Congress —  January 24-25, 2011, Washington, DC
Hear from a dozen CCOs and esteemed compliance, legal and regulatory executives from Boehringer, Cephalon, Daiichi, DDMAC, DOJ, Eisai, Endo, GSK, J&J, Lilly, Novo Nordisk, Pfizer, sanofi-aventis, UCB, U.S. Attorney’s Office and more. Thousands have benefited - Don’t miss the compliance event of the year! Register today at www.cbinet.com/pcc .

 
FindPharma  
Search  

Survey
In which business areas will you be investing to achieve more diversification in your product portfolio over the next few years?
Click To Vote
 
 
 
 
 
Quick Links

Switzerland’s Nycomed Ships API Production to India

Propoxyphene Pulled from US

Science and Politics at the FDA


Follow Pharm Exec on Twitter
Follow Pharm Exec on Facebook

User Management
| Subscribe | Update My Profile | Send Feedback | Advertise With Us | Visit PharmExec.com |

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.

Visit Pharmaceutical Executive